SPA submitted to FDA for Phase 3 CLI Program, Aastrom Biosciences (ASTM)
October 20th, 2010
No comments
ASTM has submitted to the FDA, a special protocol assessment (SPA) describing the proposed Phase 3 clinical development program in critical limb ischemia (CLI). Read more…
Categories: SPA submitted to FDA, Stem Cell Technology
